HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Sphingotec GmbH, founded in 2002 and located in Brandenburg, Germany, specializes in the development of innovative biomarkers aimed at the diagnosis, prediction, and monitoring of acute medical conditions. Their focus includes critical areas such as acute heart failure, acute kidney injury, and circulatory shock, providing essential tools for healthcare professionals in managing these serious health issues. The company’s advancements in biomarker technology contribute significantly to improving patient outcomes in acute medical scenarios.
Vascular Dynamics, Inc. develops and commercializes a catheter-delivered implant for the treatment of drug-resistant hypertension. It offers MobiusHD, an hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure to stimulate vasodilation, reduce heart rate, modulate kidney response, and decrease blood pressure. The company was founded in 2008 and is based in Irvine, California.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
1000Farmacie SRL is an Italian company based in Naples that operates an online platform for retail pharmacies. The platform offers a diverse selection of products authorized for online sale, including pharmaceuticals, cosmetics, food supplements, and pet care items, all bearing the CE guarantee mark. By facilitating the purchase of healthcare products from authorized pharmacies, 1000Farmacie enables customers to obtain these items at competitive prices. The company also provides a same-day delivery service to specified locations, enhancing convenience for its users and allowing them to save both time and money.
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.
SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on the research, discovery, and development of drugs for central nervous system disorders. Founded in 2011 and headquartered in Seongnam, the company is advancing several clinical candidates, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome. Additionally, Relenopride is in Phase 2 trials for a rare neurological disease, while SKL13865, SKL20540, SKL-PSY, and SKL24741 are in various early-phase trials for conditions such as attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to become a leading specialty pharmaceutical company by developing innovative therapies for CNS and metabolic disorders, alongside providing specialized pharmaceutical manufacturing services.
Ignis Therapeutics
Series A in 2021
Ignis Therapeutics is a life science company developing innovative therapies in the field of the central nervous system. With a strong commitment to self-discovery and a development strategy to advance the treatment paradigm, Ignis Therapeutics transforms the approach to treating CNS conditions. Ignis Therapeutics is dedicated to developing products that significantly improve the lives of patients while also providing additional therapeutic options for physicians.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company's lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate aimed at treating soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, a CAB ADC targeted at non-small cell lung cancer and melanoma, as well as BA3071, which is an anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers including renal cell carcinoma and bladder cancer. Utilizing proprietary platforms for antibody discovery and optimization, BioAtla aims to create safer and more effective cancer treatments by enhancing selectivity for tumor tissues while minimizing effects on normal tissues. The company holds over 150 issued patents and applications related to its innovative therapeutic approaches, which have the potential to address previously untreatable cancers.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
C Ray Therapeutics
Series A in 2021
C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.
Sphingotec GmbH, founded in 2002 and located in Brandenburg, Germany, specializes in the development of innovative biomarkers aimed at the diagnosis, prediction, and monitoring of acute medical conditions. Their focus includes critical areas such as acute heart failure, acute kidney injury, and circulatory shock, providing essential tools for healthcare professionals in managing these serious health issues. The company’s advancements in biomarker technology contribute significantly to improving patient outcomes in acute medical scenarios.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on the licensing, development, and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. Established in 2007, Neurelis aims to address unmet medical needs through its differentiated approach and the application of novel technologies, which are intended to enhance therapeutic benefits and improve patient care.
ValCare, Inc., a medical device company, designs and develops devices and accessories for minimally invasive treatment of heart valve disease. The company was founded in 2012 and is based in Irvine, California.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China.
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Established in 2017, the company is advancing a pipeline of transformative biotherapeutics aimed at treating cancer. Werewolf Therapeutics creates medicines intended for systemic delivery that remain inactive within the body until they arrive at the tumor microenvironment. At this point, the treatments activate to stimulate a robust immune response, thereby targeting and attacking cancer cells effectively.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Instil Bio is a clinical-stage biotechnology company specializing in the development and commercialization of tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company utilizes a patient's own T cells, harvested from their tumor, which are expanded and reinfused to effectively target and destroy cancer cells. Founded in 2018 and headquartered in Dallas, Texas, Instil Bio is advancing a pipeline of TIL therapies, including ITIL-306, which incorporates a novel genetically engineered approach through its Co-Stimulatory Antigen Receptor (CoStAR) platform. This innovative therapy aims to recognize tumor-associated antigens present in various solid tumors, such as ovarian, uterine, non-small cell lung, and renal cancers. The company is engaged in clinical trials and is supported by a team of experts in cell therapy and significant institutional investment. Additionally, Instil Bio has manufacturing and research facilities in the greater Los Angeles area and Manchester, UK.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.
Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products.
Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs.
Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on the licensing, development, and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. Established in 2007, Neurelis aims to address unmet medical needs through its differentiated approach and the application of novel technologies, which are intended to enhance therapeutic benefits and improve patient care.
BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, BioShin operates as a wholly-owned subsidiary of Biohaven Pharmaceutical Holding Company. The company is engaged in advancing clinical trials for various therapeutic approaches, including calcitonin gene-related peptide (CGRP) receptor antagonism aimed at treating migraine and pain, glutamate modulation targeting Alzheimer’s disease and anxiety disorders, and myeloperoxidase (MPO) inhibition to address inflammation and neurodegeneration. With a commitment to the Asia-Pacific region, BioShin leverages expertise from both global industry and academic settings to develop its late-stage product candidates.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Sphingotec GmbH, founded in 2002 and located in Brandenburg, Germany, specializes in the development of innovative biomarkers aimed at the diagnosis, prediction, and monitoring of acute medical conditions. Their focus includes critical areas such as acute heart failure, acute kidney injury, and circulatory shock, providing essential tools for healthcare professionals in managing these serious health issues. The company’s advancements in biomarker technology contribute significantly to improving patient outcomes in acute medical scenarios.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.
Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company's lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate aimed at treating soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, a CAB ADC targeted at non-small cell lung cancer and melanoma, as well as BA3071, which is an anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers including renal cell carcinoma and bladder cancer. Utilizing proprietary platforms for antibody discovery and optimization, BioAtla aims to create safer and more effective cancer treatments by enhancing selectivity for tumor tissues while minimizing effects on normal tissues. The company holds over 150 issued patents and applications related to its innovative therapeutic approaches, which have the potential to address previously untreatable cancers.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
Guangdong Jianke Pharmaceutical Co., Ltd. owns and operates nine pharmacy stores in China. The company also operates an online pharmacy retail store. It offers hepatobiliary, dermatology, pediatric, and urology medicines; female medication; medicines for digestive system, nervous system, and respiratory system; nourishing health care products; medical instruments; and beauty care products. The company was founded in 2006 and is based in Dongguan, China.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California. Founded in 2007, it focuses on providing rapid diagnostic testing solutions for healthcare professionals and researchers. The company has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify the binding of biomolecules, such as antibodies and proteins. This platform enables direct measurement of protein interactions, which is essential for various applications, including monitoring autoimmune diseases, screening for cancer biomarkers, and detecting infectious agents like Ebola. Genalyte's technology is also employed by pharmaceutical companies and academic researchers in their diagnostic and therapeutic efforts, making it a significant player in the life sciences sector.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.
Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
MicroOptx, Inc., a medical device company, manufactures and markets medical devices for Glaucoma. The company manufactures Beacon Aqueous Microshunt (BAM), a medical device to shunt aqueous humor from the anterior chamber to the surface of the eye. It also manufactures SalVO, a novel ab externo Minimally Invasive Glaucoma Surgery (MIGS) micro implant for the treatment of glaucoma in animals. The company was founded in 2014 and is based in Maple Grove, Minnesota.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Vascular Dynamics, Inc. develops and commercializes a catheter-delivered implant for the treatment of drug-resistant hypertension. It offers MobiusHD, an hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure to stimulate vasodilation, reduce heart rate, modulate kidney response, and decrease blood pressure. The company was founded in 2008 and is based in Irvine, California.
Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on developing treatments for severe inflammation and autoimmune diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, aimed at treating conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. The company is also advancing additional candidates, including VIB4920 for kidney transplantation rejection and Sjögren’s syndrome, as well as VIB7734 for cutaneous lupus erythematosus. Viela Bio has formed a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, the company is dedicated to addressing unmet medical needs in the field of autoimmune disorders.
Cathay Biotech is a leading global company based in Shanghai, China, specializing in synthetic biology and bio-manufacturing to produce sustainable materials from renewable sources. The firm focuses on developing long-chain dibasic acids and bio-based pentamethylene diamine, positioning itself as the first commercial producer of pentanediamine from renewable materials. These innovations enable the production of unique polyamides, which are utilized in engineering polymers and textiles, thereby offering environmentally friendly alternatives to traditional chemical processes. The company's bio-production technique employs biomass and other raw materials under mild conditions, significantly reducing environmental impact and enhancing economic efficiency. Cathay Biotech aims to mitigate the reliance on conventional chemicals while addressing related environmental and safety concerns. The company operates research and development facilities in Zhangjiang Hi-Tech Park, Shanghai, and has production sites in Jinxiang and Wusu, both located in Shandong and Xinjiang provinces, respectively.
Vascular Dynamics, Inc. develops and commercializes a catheter-delivered implant for the treatment of drug-resistant hypertension. It offers MobiusHD, an hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure to stimulate vasodilation, reduce heart rate, modulate kidney response, and decrease blood pressure. The company was founded in 2008 and is based in Irvine, California.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.
The company was founded in 2017 and headquartered in Connecticut, United States.
NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.
SAI is an ideal drug discovery, development and manufacturing partner. Their pharma and biotech clients gain clear competitive advantages through shorter time to market and risk minimization using their integrated and high-quality scientific services.
SAI’s mission is to help their partners develop innovative medicines quicker and at lower cost by providing reliable research and manufacturing solutions. Their guiding principles are to be reliable, communicate effectively, safeguard IP, invest in people and to adopt technologies.
At SAI Life Sciences, developing a business relationship with their clients that benefits both parties is only the beginning. They have learned through experience, it is when they build a partnership with a customer, that they can truly amplify their mutual interests and successes. At SAI they will call this “+1” and it hints at the additional value they aim to find mutually in longer term relationships.
Vascular Dynamics, Inc. develops and commercializes a catheter-delivered implant for the treatment of drug-resistant hypertension. It offers MobiusHD, an hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure to stimulate vasodilation, reduce heart rate, modulate kidney response, and decrease blood pressure. The company was founded in 2008 and is based in Irvine, California.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Sphingotec GmbH, founded in 2002 and located in Brandenburg, Germany, specializes in the development of innovative biomarkers aimed at the diagnosis, prediction, and monitoring of acute medical conditions. Their focus includes critical areas such as acute heart failure, acute kidney injury, and circulatory shock, providing essential tools for healthcare professionals in managing these serious health issues. The company’s advancements in biomarker technology contribute significantly to improving patient outcomes in acute medical scenarios.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Guangdong Jianke Pharmaceutical Co., Ltd. owns and operates nine pharmacy stores in China. The company also operates an online pharmacy retail store. It offers hepatobiliary, dermatology, pediatric, and urology medicines; female medication; medicines for digestive system, nervous system, and respiratory system; nourishing health care products; medical instruments; and beauty care products. The company was founded in 2006 and is based in Dongguan, China.